APMAdvances in Precision Medicine2424-85922424-9106WHIOCE PUBLISHING PTE. LTD.10.18063/APM.v11i2.1425ArticleCore Execution Mechanisms of Ferroptosis in Prostate Cancerhttps://artdesignp.com/journal/APM/11/2/10.18063/APM.v11i2.1425HeHongxiang,JiangJunfeng20261122026-02-26Prostate cancer (PCa) progression to castration-resistant disease remains a clinical challenge driven by therapeutic resistance. Ferroptosis, an iron-dependent regulated cell death, offers a promising strategy to overcome this resistance. This review elucidates the core execution mechanisms of ferroptosis in PCa across three primary levels. First, we examine the interplay between lipid peroxidation and antioxidant systems, highlighting the pivotal roles of GPX4, System Xc⁻, and ACSL4. Second, we discuss the regulation of iron metabolism, encompassing uptake, storage, and ferritinophagy mediated by proteins like TfR1 and NCOA4. Third, we explore mitochondrial function and oxidative stress responses, emphasizing metabolic reprogramming and ROS generation. By dissecting these intricate pathways, including GPX4-independent surveillance mechanisms, we aim to identify novel therapeutic targets. Understanding these mechanisms provides critical insights for developing targeted therapies that sensitize resistant tumors to ferroptosis, ultimately improving PCa management and overcoming limitations of conventional androgen deprivation therapies.Prostate cancer,Ferroptosis,Lipid peroxidation,Iron metabolism,GPX4,Therapeutic resistance

[1] Li Y, Zhang B, Zhang Z, et al., 2026, Inhibition of the RORC/GPX4 Mediated Ferroptosis Regulatory Axis Suppresses Tumor Growth and Alleviates Enzalutamide Resistance in Prostate Cancer. Cell Mol Biol Lett, 31(1): 11. [2] Xu L, Wang X, Xu Y, et al., 2025, Discovery of a Selenium-Containing Compound as a Promising Ferroptosis Inducer Attenuates Prostate Cancer Progression. Eur J Med Chem, 299: 118067. [3] Zhang Z, Xie T, Zhang S, et al., 2023, Second Generation Androgen Receptor Antagonist, TQB3720 Abrogates Prostate Cancer Growth via AR/GPX4 Axis Activated Ferroptosis. Front Pharmacol, 14: 1110146. [4] Xu P, Wang Y, Deng Z, et al., 2022, MicroRNA-15a Promotes Prostate Cancer Cell Ferroptosis by Inhibiting GPX4 Expression. Oncol Lett, 23(2): 67. [5] Li Q, Chen D, Xia Y, et al., 2026, Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer. Adv Sci (Weinh), e15340. [6] Sun R, Yan B, Li H, et al., 2023, Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res, 83(19): 3192–3204. [7] Tang M, Xue L, Wang B, et al., 2025, SLC7A11 Upregulation via AR and NEDD4L Ubiquitination Contributes to Ferroptosis Inhibition and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. Cell Death Dis, 16(1): 591. [8] Jiang X, Guo S, Xu M, et al., 2022, TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer through c-Myc/miR-25-3p/SLC7A11 Signaling. Front Oncol, 12: 862015. [9] Wang J, Zeng L, Wu N, et al., 2023, Inhibition of Phosphoglycerate Dehydrogenase Induces Ferroptosis and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells. Drug Resist Updat, 70: 100985. [10] Jian J, Xu H, Shi X, et al., 2026, Imperatorin Induces Ferroptosis via Mediating Lipid Peroxidation and SLC7A11/ACSL4/GPX4 Signaling for Inhibition and Therapeutics of Prostate Cancer. Biochem Pharmacol, 245: 117683. [11] Shao S, Li W, Hong Y, et al., 2026, ZDHHC2-Dependent Palmitoylation Dictates Ferroptosis and Castration Sensitivity in Prostate Cancer via Controlling ACSL4 Degradation and Lipid Peroxidation. Adv Sci (Weinh), 13(1): e14077. [12] Xie W, Agarwal S, Yu J, 2023, Ferroptosis: The Vulnerability within a Cancer Monster. J Clin Invest, 133(10): e170027. [13] Wang M E, Chen J, Lu Y, et al., 2023, RB1-Deficient Prostate Tumor Growth and Metastasis Are Vulnerable to Ferroptosis Induction via the E2F/ACSL4 Axis. J Clin Invest, 133(10): e166647. [14] Zou P, Chen Z, He Q, et al., 2024, Polyphyllin I Induces Ferroptosis in Castration-Resistant Prostate Cancer Cells through the ERK/DNMT1/ACSL4 Axis. Prostate, 84(1): 64–73. [15] Liang D, Feng Y, Zandkarimi F, et al., 2023, Ferroptosis Surveillance Independent of GPX4 and Differentially Regulated by Sex Hormones. Cell, 186(13): 2748-2764.e22. [16] Vermonden P, Martin M, Glowacka K, et al., 2024, Phospholipase PLA2G7 Is Complementary to GPX4 in Mitigating Punicic-Acid-Induced Ferroptosis in Prostate Cancer Cells. iScience, 27(5): 109774. [17] Li B, Cheng B, Huang H, et al., 2024, Darolutamide-Mediated Phospholipid Remodeling Induces Ferroptosis through the SREBP1-FASN Axis in Prostate Cancer. Int J Biol Sci, 20(12): 4635–4653. [18] Yi J, Zhu J, Wu J, et al., 2020, Oncogenic Activation of PI3K-AKT-mTOR Signaling Suppresses Ferroptosis via SREBP-Mediated Lipogenesis. Proc Natl Acad Sci U S A, 117(49): 31189–31197. [19] Nassar ZD, Mah CY, Dehairs J, et al., 2020, Human DECR1 Is an Androgen-Repressed Survival Factor That Regulates PUFA Oxidation to Protect Prostate Tumor Cells from Ferroptosis. Elife, 9: e54166. [20] Blomme A, Ford CA, Mui E, et al., 2020, 2, 4-Dienoyl-CoA Reductase Regulates Lipid Homeostasis in Treatment-Resistant Prostate Cancer. Nat Commun, 11(1): 2508. [21] Li Z, Zhang W, Xu Y, et al., 2025, Metformin-Amplified Ferroptosis Induced by Ultrasmall Manganese Ferrite Nanoparticles: A GPX4-Independent Strategy for Prostate Cancer Therapy. J Nanobiotechnology, 24(1): 11. [22] Basaran E, Hacioglu C, Baba D, et al., 2025, Borax Triggers Ferroptosis by Modulating the TfR1/GPX4/ACSL4 Pathway in Prostate Cancer Cells with Differential Androgen Sensitivity. Biol Trace Elem Res, 203(12): 6542–6558. [23] Wang H, Fang D, Zhu J, et al., 2024, Ferroptosis-Related Gene Signature Predicts Prognosis and Immune Microenvironment in Prostate Cancer. Transl Androl Urol, 13(9): 2092–2109. [24] Ma S, Ge Y, Lu Z, et al., 2025, Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer. Cancer Res, 85(19): 3771–3790. [25] Park B, Khadka S, Ahn J, et al., 2025, Ferroptosis Induction, Androgen Biosynthesis Disruption and Prostate Cancer Suppression by Androgen and Vitamin D Combination. Biochim Biophys Acta Gen Subj, 1869(8): 130828. [26] Fu W, Xu L, Chen Y, et al., 2024, Luteolin Induces Ferroptosis in Prostate Cancer Cells by Promoting TFEB Nuclear Translocation and Increasing Ferritinophagy. Prostate, 84(3): 223–236. [27] Yu G, Chen K, Xu B, et al., 2025, Mitochondrial SLC25A10 Promotes Prostate Cancer Progression by Inhibiting Ferritinophagy. Cell Death Discov, 11(1): 242. [28] Maccarinelli F, Coltrini D, Mussi S, et al., 2023, Iron Supplementation Enhances RSL3-Induced Ferroptosis to Treat Naïve and Prevent Castration-Resistant Prostate Cancer. Cell Death Discov, 9(1): 81. [29] Yang G, Pan Q, Lu Y, et al., 2023, miR-29a-5p Modulates Ferroptosis by Targeting Ferritin Heavy Chain FTH1 in Prostate Cancer. Biochem Biophys Res Commun, 652: 6–13. [30] Lu J, Zou Q, Li Y, et al., 2024, FTH1P8 Induces and Transmits Docetaxel Resistance by Inhibiting Ferroptosis in Prostate Cancer. Biomed Pharmacother, 180: 117472. [31] Yang J, Lu X, Hao J L, et al., 2025, VSTM2L Protects Prostate Cancer Cells against Ferroptosis via Inhibiting VDAC1 Oligomerization and Maintaining Mitochondria Homeostasis. Nat Commun, 16(1): 1160. [32] Chen YY, Hua WX, Huang YH, et al., 2025, Polyphyllin VII Enhances the Sensitivity of Prostate Cancer Cells to Docetaxel by Promoting Mitochondrial Dysfunction and Inducing Ferroptosis. Chem Biol Drug Des, 105(2): e70053. [33] He Z, Shi J, Zhu B, et al., 2025, Ginsenoside RH2 Repressed the Progression of Prostate Cancer through the Mitochondrial Damage Induced by Mitophagy and Ferroptosis. Front Oncol, 15: 1633891. [34] Jia G, Wu W, Chen L, et al., 2023, HSF1 Is a Novel Prognostic Biomarker in High-Risk Prostate Cancer That Correlates with Ferroptosis. Discov Oncol, 14(1): 107. [35] Nikoo A, Roudkenar MH, Sato T, et al., 2023, Mitochondrial Transfer in PC-3 Cells Fingerprinted in Ferroptosis Sensitivity: A Brand New Approach Targeting Cancer Metabolism. Hum Cell, 36(4): 1441–1450. [36] Wilfinger-Lutz N, Kuehrer KM, Bueno MJ, et al., 2026, FASN Targeting by G28UCM Impairs Mitochondrial Fatty Acid Synthesis and Reveals a FASN-SDHB Synthetic Interaction. Pharmacol Res, 224: 108087. [37] Ji FH, Qian YH, Guo XC, et al., 2025, Targeting RPS6KC1 to Overcome Enzalutamide Resistance in Prostate Cancer. Biomark Res, 13(1): 109. [38] Campbell T, Hawsawi O, Henderson V, et al., 2023, Novel Roles for HMGA2 Isoforms in Regulating Oxidative Stress and Sensitizing to RSL3-Induced Ferroptosis in Prostate Cancer Cells. Heliyon, 9(4): e14810. [39] Zhang H, Xing C, Yan B, et al., 2024, Paclitaxel Overload Supramolecular Oxidative Stress Nanoamplifier with a CDK12 Inhibitor for Enhanced Cancer Therapy. Biomacromolecules, 25(6): 3685–3702. [40] Chang WT, Bow YD, Fu PJ, et al., 2021, A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways. Oxid Med Cell Longev, 2021: 7689045. [41] Tousignant KD, Rockstroh A, Poad BLJ, et al., 2020, Therapy-Induced Lipid Uptake and Remodeling Underpin Ferroptosis Hypersensitivity in Prostate Cancer. Cancer Metab, 8: 11.